Cord Blood Therapy to prevent progression of COVID-19 related pneumonia

Monash Health0 sites24 target enrollmentApril 16, 2020

Overview

No summary available.

Registry

who.int

Start Date

April 16, 2020

End Date

TBD

Last Updated

3 years ago

Study Type

Interventional

Sex

All

Sponsor

•Hospitalised patients with confirmed SARS\-CoV2 infection (based on appropriate nucleic acid or other testing), and
•1\)Expected to remain an in\-patient for at least 48 hours with
•2\)Features consistent with viral pneumonia on Chest CT or X\-Ray (in the opinion of the investigator) and
•3\)Are unable to maintain a peripheral oxygen saturation of 95% or greater in room air

•1\)Patients with known allergies to stem cell preparations
•2\)Patients with known significant lung disease before COVID\-19 presentation
•3\)Receiving invasive/ mechanical ventilatory support
•4\)Patients with underlying disease, comorbidities or clinical status that in the opinion of the investigator suggests death is imminent and/or likely to occur the next 48 hours
•5\)Currently on other investigational stem cell therapies
•6\)Known pregnancy
•7\)Patient unable to provide consent
•8\)The treating team deems that enrolment in the study is not in the best interests of the patient.